Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers

Area of Science:

• Oncology
• Nanomedicine
• Biotechnology

Background:

• Cancer treatment response varies significantly, with high-dose chemotherapy causing severe side effects, particularly in triple-negative breast cancer.
• Current targeted drug delivery methods, while improving pharmacokinetics, have not fully achieved desired clinical outcomes.
• There is a critical need for novel therapeutic strategies that specifically target and eliminate tumor cells while minimizing toxicity.

Purpose of the Study:

• To review the current landscape of breast cancer classification and standard treatments.
• To explore the application of nanomedicine in breast cancer therapy.
• To discuss ultrasound-responsive biocompatible carriers for targeted drug and gene delivery.

Main Methods:

• Review of existing literature on breast cancer treatment standards.
• Analysis of nanomedicine applications in preclinical breast cancer models.
• Examination of various ultrasound-responsive carriers including micro/nanobubbles, liposomes, micelles, polymeric nanoparticles, and nanodroplets/nanoemulsions.

Main Results:

• Nanomedicine and ultrasound-responsive carriers show promise in preclinical studies for enhanced drug and gene delivery to breast tumors.
• These systems offer potential for targeted therapy, aiming to increase drug concentration at the tumor site.
• The reviewed carriers represent diverse approaches to overcoming delivery challenges in breast cancer treatment.

Conclusions:

• Nanomedicine and advanced carrier systems are crucial for developing more effective and less toxic breast cancer treatments.
• Ultrasound-responsive carriers provide a platform for spatiotemporal control of drug release, enhancing therapeutic precision.
• Further preclinical investigation is warranted to translate these promising nanotechnologies into clinical applications for breast cancer patients.